Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes
Start of patient enrolment on 21st of June 2016
2571 patients enrolled (2502 patients randomised)
181 sites open for recruitment
Status as of 11th of July 2022
Planned number of participants
36 randomised and treated patients pending to archieve recruitment target
17 european countries:
Belgium, Bulgaria, Germany, France, Greece, United Kingdom, Italy, The Netherlands, Austria, Poland, Portugal, Romania, Sweden, Spain, Czech Republic, Ukraine, Hungary
Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, deGroot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, and Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019; 0, 1–9.
Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G, Diener HC, Kirchhof P. Atrial high-rate episodes and stroke prevention. Europace. 2017 Feb 1;19(2):169-179. doi: 10.1093/europace/euw279. Epub 2016 Feb 29.
Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.
Atrial Fibrillation NETwork (AFNET), Münster, Germany
International Chief Investigator:
Prof. Paulus Kirchhof, Hamburg, Germany